# M108

Source: https://onco.cc/drugs/m108/  
OnCo record `m108` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

M108 is an experimental monoclonal antibody from FutureGen Biopharmaceutical (Beijing) in phase 3 trials for gastric & gastro-oesophageal junction cancer, aimed at Claudin 18.2.

## Summary

M108 is a monoclonal antibody developed by FutureGen Biopharmaceutical (Beijing). Its target is Claudin 18.2 (the sponsor names Claudin 18.2 (CLDN18.2)). ClinicalTrials.gov describes the intervention as: M108 monoclonal antibody will be administered as a minimum 2-hour IV infusion. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06177041 (M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma), in gastric & gastro-oesophageal junction cancer. The largest, NCT06177041, plans to enrol 486 participants with primary completion expected 2027-01-11. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Also known as: M108 monoclonal antibody
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at Claudin 18.2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of M108: https://clinicaltrials.gov/search?intr=M108

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/)
- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- trials: [M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma](https://onco.cc/trials/nct06177041/)

---
JSON: https://onco.cc/api/v1/entities/m108.json